Intracerebral delivery of hCNTF has shown considerable neuroprotective potential in animal models of Huntington's disease (HD). The present study describes the relationship between a range of hCNTF doses and the resulting behavioral and neurochemical (striatal ChAT and GAD activity) protection in a rodent model of HD. Encapsulated BHK delivering a range of hCNTF doses were implanted into the lateral ventricle ipsilateral to an intrastriatal quinolinic acid (QA) injection. Results demonstrated a dose-dependent effect of hCNTF with complete, partial, and no observable neuroprotection occurring with preimplant doses of hCNTF of 30.8, 8.6, and 0.8–2.1 ng hCNTF/24 h, respectively. These data continue to support the use of cellular delivery of hCNTF for HD and will facilitate the optimization of this approach in the clinical situation.
Bachoud-LeviA. C.; DeglonN.; NguyenJ.-P.; BlochJ.; BourdetC.; WinkelL.; RemyP.; GoddardM.; LefaucherJ. P.; BrugieresP.; BaudicS.; CesaroP.; PeschanskiM.; AebischerP.Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF.Hum. Gene Ther.11: 1723–1729; 2000.
2.
ChoiD. W.Glutamate neurotoxicity and diseases of the nervous system.Neuron1: 623–634; 1988.
3.
deAlmeidaL. P.; ZalaD.; AebischerP.; DeglonN.Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease.Neurobiol. Dis.8: 433–446; 2001.
4.
EmerichD. F.; HammangJ. P.; BaetgeE. E.; WinnS. R.Implantation of polymer-encapsulated human nerve growth factor-secreting fibroblasts attenuates the behavioral and neuropathological consequences of quinolinic acid injections into rodent striatum.Exp. Neurol.130: 141–150; 1994.
5.
EmerichD. F.; WinnS. R.; LindnerM. D.; FrydelB. R.; KordowerJ. H.Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease.J. Neurosci.16: 5168–5181; 1996.
6.
EmerichD. F.; CainC. K.; GrecoC.; SaydoffJ. A.; HuZ. -Y.; LiuH.; LindnerM. D.Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease.Cell Transplant.6: 249–266; 1997.
7.
EmerichD. F.; WinnS. R.; ChenE.-Y.; ChuY.; McDermottP.; BaetgeE.; KordowerJ. H.Protection of basal ganglia circuitry by encapsulated CNTF-producing cells in a primate model of Huntington's disease.Nature386: 395–399; 1997.
8.
EmerichD. F.; WinnS. R.Neuroprotective effects of encapsulated CNTF-producing cells in a rodent model of Huntington's disease are dependent on the proximity of the implant to the lesioned striatum.Cell Transplant.13: 253–259; 2004.
9.
FrimD. M.; SchumacherJ. M.; ShortM. P.; BreakefieldX. O.; IsacsonO.Local response to intracerebral grafts of NGF-secreting fibroblasts: Induction of a peroxidative enzyme.Soc. Neurosci. Abstr.18: 1100; 1992.
10.
FrimD. M.; UhlerT. A.; ShortM. P.; ExxedineZ. D.; KlagsbrunM.; BreakefieldX. O.; IsacsonO.Effects of biologically delivered NGF, BDNF, and bFGF on striatal excitotoxic lesions.Neuroreport4: 367–370; 1993.
11.
FrimD. M.; SimpsonJ.; UhlerT. A.; ShortM. P.; BossiS. R.; BreakefieldX. O.; IsacsonO.Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF.J. Neurosci. Res.35: 452–458; 1993.
12.
JacksonG.; ApffelL.; Werrbach-PerezK.; Perez-PoloJ. R.Role of nerve growth factor in oxidant-antioxidant balance and neuronal injury. I. Stimulation of hydrogen peroxide resistance.J. Neurosci. Res.25: 360–368; 1990.
13.
KordowerJ. H.; ChenE.-Y.; MufsonE. J.; WinnS. R.; EmerichD. F.Intrastriatal implants of polymer-encapsulated cells genetically modified to secrete human NGF: Trophic effects upon cholinergic and noncholinergic neurons.Neuroscience72: 63–77; 1996.
14.
KordowerJ. H.; IsacsonO.; EmerichD. F.Cellular delivery of trophic factors for the treatment of Huntington's disease: Is neuroprotection possible? Exp.Neurol.159: 4–20; 1999.
15.
MacLennanJ. A.; VinsonE. N.; MarksL.; McLaurainD. L.; PfieferM.; LeeM.Immunohistochemical localization of ciliary neurotrophic factor receptor alpha expression in the rat nervous system.J. Neurosci.16: 621–630; 1996.
16.
MattsonM. P.; ChengB.; Smith-SwintoskyV. L.Mechanisms of neurotrophic factor protection against calcium- and free radical-mediated excitotoxic injury: Implications for treating neurodegenerative disorders.Exp. Neurol.124: 89–95; 1993.
17.
MittouxV.; JosephJ. M.; CondeF.; PalfiS.; DautryC.; PoyotT.; BlochJ.; DeglonN.; OuaryS.; NimchinskyE. A.; BrouilletE.; HofP. l R.; PeschanskiM.; AebischerP.; HantrayeP.Restoration of cognitive and motor function with ciliary neurotrophic factor in a primate model of Huntington's disease.Hum. Gene. Ther.11: 1177–1187; 2000.
18.
MittouxV.; QuaryS.; MonvilleC.; LisovoskiF.; PoyotT.; CondeF.; EscartinC.; RobichonR.; BrouilletE.; PeschanskiM.; HantrayeP.Corticostriatopallidal neuro-protection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration.J. Neurosci.22: 4478–4486; 2002.
19.
PenneyJ. B.; YoungA. B.; ShoulsonI.Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals.Mov. Disord.5: 93–99; 1990.
20.
RegulierE.; Perreira de AlmeidaL.; SommerB.; AebischerP.; DeglonN.Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease.Hum. Gene Ther.13: 1981–1990; 2002.
21.
RothmanS. M.The neurotoxicity of excitatory amino acids is produced by passive chloride influx.J. Neurosci.5: 1483–1490; 1985.
22.
SendtnerM.; GnahnH.; WadakeA.; ThoenenH.Is the action of Na+/K+ pump necessary for NGF-mediated neuronal survival? J.Neurosci.8: 458–462; 1988.
23.
ShoulsonI.Huntington's disease: Functional capacities in patients treated with neuroleptic and antidepressant drugs.Neurology31: 1333–1335; 1981.
24.
The Huntington's Disease Collaborative Research Group.A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.Cell72: 971–978; 1993.
25.
WinnS. R.; LindnerM. D.; HaggettG.; FrancisJ. M.; EmerichD. F.Polymer-encapsulated genetically-modified cells continue to secrete human nerve growth factor for over one year in rat ventricles: Behavioral and anatomical consequences.Exp. Neurol.140: 126–138; 1996.
